Halozyme Therapeutics (HALO) PT Raised to $26 at Citi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Halozyme Therapeutics (HALO) PT Raised to $26 at Citi

Halozyme Therapeutics (HALO) Reports Data from Janssen's Ph. 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE in Light-Chain Amyloidosis

June 15, 2020 5:58 AM EDT

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE® in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed light-chain (AL)... More